RecruitingPHASE1, PHASE2NCT07540338
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alzamend Neuro, Inc.
- Intervention
- AL001(drug)
- Enrollment
- 20 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2026 – 2026
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07540338 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07343778A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGPHASE2NCT07364448A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGNANCT06544018Circadian Rhythm Deregulation in Patients With CAPSHospices Civils de Lyon
- RECRUITINGNANCT07203963Additional Effects of Niel-asher Technique on Patients With Adhesive CapsulitisRiphah International University
- RECRUITINGPHASE1NCT07532135Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy VolunteerChulalongkorn University
- RECRUITINGPHASE4NCT07114120Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE3NCT06930794A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveBeijing Pearl Biotechnology Limited Liability Company
- RECRUITINGPHASE2, PHASE3NCT06931080Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsOtsuka Pharmaceutical Co., Ltd.
See all trials for NLRP3-associated autoinflammatory disease →